News Search Results
Sep 22, 2025, 13:23 ET Rubin Rudman Partners Ariadna Caulfield and Marlee S. Cowan Elected to Massachusetts Bar Association Leadership Roles
Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin Rudman
Sep 22, 2025, 11:31 ET Hydrogen Fuel Cell (HFC) Market Size & Share to Surpass $42.3 Billion by 2035, Growing at a CAGR 20% | Powering the Future of Clean Energy, Transportation, and Industrial Transformation
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Sep 22, 2025, 11:30 ET Lab Automation Market is Projected To Reach US$8.71 Billion By 2031 at CAGR of 6.3% | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.
More news about: The Insight Partners
Sep 22, 2025, 11:16 ET RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare Diseases, Oncology, and Advances in RNA Technologies | DataM Intelligence
and is projected to grow at double-digit rates. Key growth factors include: Increasing government investments in advanced biotechnology.Partnerships between Japanese firms and global biopharma for RNAi and ASO therapies.PMDA's regulatory flexibility, supporting
More news about: DataM Intelligence 4 Market Research LLP
Sep 22, 2025, 11:14 ET Global Office Sleep Pod Market Expected to Surge to USD 550 Million by 2033, Growing at a Robust CAGR of 12.5% from 2026 to 2033 - Market Research Intellect
Analytics Tools, Patent Valuation Software, Patent Management Systems, Patent Portfolio Management Tools), By End-User Industries (Pharmaceuticals, Biotechnology, Information Technology, Automotive, Manufacturing), By Deployment Type (Cloud-Based, On-Premises, Hybrid), Regional Analysis, And Forecast
More news about: Market Research Intellect
Sep 22, 2025, 11:01 ET Electronic Signature Software Market Is Projected To Reach US$35.71 Billion By 2031 At CAGR Of 34.6% | Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 22, 2025, 10:30 ET Conveyor System Market is Projected To Reach US$9.40 Billion By 2031 at CAGR of 5.7% | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 22, 2025, 10:08 ET Antibiotics Market Size to Surpass USD 55.26 Billion by 2033, Report by DataM Intelligence
sepsis, pneumonia, urinary tract infections, and hospital-acquired illnesses. New product development is also accelerating because of developments in biotechnology, quick diagnostics, and medication discovery, while antibiotic R&D and market entrance are being supported by government programs and regulatory
More news about: DataM Intelligence 4 Market Research LLP
Sep 22, 2025, 10:01 ET Data Center Colocation Market is Projected To Reach US$182.58 Billion By 2031 at CAGR of 13.7% | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 22, 2025, 09:05 ET Congruence Therapeutics Earns "Fierce 15" Distinction for 2025
computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, today announced that Fierce Biotech has named it as one of 2025's Fierce 15 biotechnology companies, honoring it as one of the most innovative and promising private biotechnology companies
More news about: Congruence Therapeutics
Sep 22, 2025, 09:00 ET MavriX Bio Receives FDA Fast Track Designation for MVX-220 for Treatment of Angelman Syndrome
Mass., Sept. 22, 2025 /PRNewswire/ -- MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the U.S. Food and Drug Administration
More news about: AS2Bio
Sep 22, 2025, 08:44 ET True Indicating: The Innovation-Driven Company Reinventing Sterilization Science
disinfection monitoring products and expert services to medical device manufacturers, healthcare, dental, laboratory service providers, life science, biotechnology companies, industrial, and pharmaceutical manufacturers, The company has over 35 years of combined experience, with a focus on science-based service.
More news about: True Indicating
Sep 22, 2025, 08:30 ET Patient Recruitment Strategies: Fixing the Friction in Trial Enrollment, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 22, 2025, 08:30 ET Biomarker Discovery: Integrating Proteomics and Genomics for Comprehensive Biological Insights, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 22, 2025, 08:30 ET BYOD or Bust: Are Clinical Trials Ready for the Device Revolution? Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 22, 2025, 08:30 ET Enhancing Clinical Trials in Obesity by Integrating Clinical Outcome Assessments and Digital Health Technologies, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 22, 2025, 08:05 ET Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that final results from the Phase 1 clinical trial of its breast cancer
More news about: Anixa Biosciences, Inc.
Sep 22, 2025, 08:00 ET Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis
Sept. 22, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today
More news about: Coya Therapeutics, Inc.
Sep 22, 2025, 07:30 ET Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
Sep 22, 2025, 00:15 ET First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs
(ADCC) and Fc engineering for an extended half-life. About Leads Biolabs Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology,
More news about: Leads Biolabs
Sep 21, 2025, 20:29 ET AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis B
/PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), today announced
More news about: AusperBio Therapeutics Inc.
Sep 21, 2025, 20:10 ET Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy
was four weeks and the follow-up period was six weeks. About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Sep 20, 2025, 08:00 ET Do you own shares of KBR? Robbins LLP Informs Investors of the Jasper Therapeutics, Inc. Class Action Lawsuit
JSPR) securities between November 30, 2023 and July 3, 2025. Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible
More news about: Robbins LLP
Sep 19, 2025, 20:07 ET Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY™ (elamipretide HCl), the First Therapy for Progressive and Life-limiting Ultra-rare Genetic Disease Barth Syndrome
Sept. 19, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced
More news about: Stealth BioTherapeutics Inc.
Sep 19, 2025, 12:34 ET FDA Greenlights HDT Bio's First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease
Sept. 19, 2025 /PRNewswire/ -- HDT Bio Corporation, a U.S.-based clinical-stage biotechnology company advancing immune-enhancing solutions for global health, biodefense, and oncology, today announced that the U.S. Food and Drug Administration
More news about: HDT Bio Corp.